EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib

摘要: It has been reported that the threonine-to-methionine substitution at amino acid position 790 (T790M) of epidermal growth factor receptor (EGFR) gene is correlated with acquired resistance to gefitinib. We previously there was some population harbored EGFR T790M mutation as a minor clone tumor cells prior drug treatment, may be causing gefitinib during treatment. This fact also suggests detection treatment predict development resistance. showed pleural fluid useful specimen for using sensitive assays. In this study, we female patient who treated because an L858R found in her fluid. Our partial response gefitinib, but she had progressive disease only 4 months after start Furthermore, detected before by mutant-enriched PCR assay. findings confirmed occasionally present and caused administration. The small fraction T790M-positive alleles clinical course gefitinib-treated non-small-cell lung cancer patients.